Nautilus Biotechnology has opened applications for an oncology-focused Iterative Mapping grant program, offering selected researchers free analysis of AKT1 or EGFR proteoforms in 12 samples. The move broadens access to its proteomics tools for cancer research.
published
Nautilus Biotechnology has opened applications for an oncology-focused Iterative Mapping grant program, offering selected researchers free analysis of AKT1 or EGFR proteoforms in 12 samples. The move broadens access to its proteomics tools for cancer research.
Latest documented BWB result
$SECZ market result
Exit $SECZ with .95 profit per share - thanks to a nice after hours pop. Will re-enter tomorrow most likely
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.